Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
SURMOUNT-2 also met all of its key secondary endpoints, with more patients in both tirzepatide groups achieving 10%, 15% and 20% body weight loss compared to patients in the placebo group, for both estimands ( Figure 9 - 19C-D )
It was based on a large sample, robust data sources, and a diverse study population
Reported effects include redness or swelling at the injection site, headache, flushing, or water retention in test models
According to a clinical primer published in the American Heart Association journal Circulation, semaglutide has been associated with lean mass making up a large share of total weight lost, by some trial estimates approaching 40 percent, and tirzepatide has shown a similar pattern at roughly a third of weight lost
US$ 28.14
US$ 28.76
US$ 25.13
US$ 26.61
US$ 27.17
US$ 22.19
